Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.
about
Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advancesTherapeutic cancer vaccines: past, present, and futureEndpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccinesRecent advances in therapeutic cancer vaccinesA Review of Modeling Approaches to Predict Drug Response in Clinical OncologyThe immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors.More data, less information? Potential for nonmonotonic information growth using GEE.Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example.Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implicationsRole of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer TreatmentA review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis.Poxviral-based vaccine elicits immunologic responses in prostate cancer patients.Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advancesImmunotherapy for metastatic solid cancersNovel therapies for metastatic castrate-resistant prostate cancer.A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T.End points of clinical trials in metastatic castration-resistant prostate cancer: A systematic reviewExploiting synergy: immune-based combinations in the treatment of prostate cancer.Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response.Impact of tumour volume on the potential efficacy of therapeutic vaccines.A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time.Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments.Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.Changing the energy habitat of the cancer cell in order to impact therapeutic resistance.Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomasProstate cancer immunotherapy.Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing.A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.Initial PSA oscillations precede prolonged stable disease in a patient treated with a therapeutic cancer vaccineTherapeutic cancer vaccines: current status and moving forward.Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth.Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer.The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitorsDisease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With EribulinOptimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy.Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validationClinical evaluation of TRICOM vector therapeutic cancer vaccinesBiomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancerImmunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research.
P2860
Q26827475-1A732870-2CE3-43B2-9760-E62C374D483FQ26863283-3E52ECDD-B09E-4962-86A0-E3DC1376A748Q27008070-D5E184C8-F656-43CD-A40B-83ACD41090ADQ27025266-A741FBC2-50CC-400C-A5B6-DE773CD0D3EBQ28066777-AC65157B-D6B4-4792-83EE-3D4B40950B46Q30414395-DD4FA9C1-DD0E-481D-A44B-1ACA49562CD0Q31069930-A07D8BD8-50A9-4285-8E73-05ECF458D36AQ33567889-E20732F3-FBA6-4942-93A4-4CB2912BE0ECQ33621393-8523BF99-ABFD-464D-86E4-234AEAB1AACBQ33718182-D9F0DA52-C3FA-473B-9C54-829E5BB3E97AQ33729213-0F2E2166-AAB7-4089-8E0B-DC0EFC59DEBCQ33879368-A01691B8-36D3-478B-A11D-DD084648CC00Q33973408-0BC1E8AB-F251-44E8-9B37-F2B468A6923EQ34219970-02B66B13-EEFF-4757-A368-DD5F7A1B83ACQ34249263-D47A1D83-981D-4169-BA12-EDD93416C26EQ34289239-2FB60359-683C-4748-A69E-29EDC49EB42AQ34367585-49437F06-84A2-481B-93AD-78380111FB95Q34687216-AC5912C5-B3E6-4771-8616-57B939DB4859Q34953673-31E82E1D-E662-47C1-B715-761505389520Q35027034-CF7246CC-0CBF-416D-B279-E6C5FEF04021Q35076925-08D1A80E-2F7A-4886-8DE7-437E40CB6593Q35128716-EE129B42-54AA-4784-A761-C8360D577A1FQ35419821-2B07FF94-7E6E-4490-B276-1B633959BACEQ35592703-9F21F265-ABD4-4CA1-9FB3-36325A968D8FQ35683306-2D4CF41C-4B72-47FB-8DF5-858D7DD671C4Q35688425-73368396-6C58-4206-B331-BD7249110BABQ35752182-5A663FAF-4B09-49E6-8AF5-70E718DA00DCQ35756538-02C508CA-E016-44E2-BDC4-5D92D97E9D91Q35757242-4B9BC29C-EBC2-46DF-9FE2-00C6B3F51561Q35894347-C26AFCD1-D7DA-4679-8B6D-48F04207C65AQ35894702-AA6820BF-CA16-447C-8958-CB3BFB522FB0Q35956673-BCE15EFF-13C9-485C-B33E-F2A5CDC05C13Q35975387-2FC8F60F-716F-44A5-885C-FA752AF8EFF8Q35979551-D8C694AD-7A57-4C84-A1EB-000407E5503FQ36046884-3221C788-C482-4793-A948-1C3775B044D9Q36076716-FF24F6F1-4527-4566-BE92-68EA06112D0DQ36099965-23FFE231-1D4E-4978-8EA1-83ED514532DAQ36243296-63D49E9D-4563-4084-A36E-86D2BF051FEDQ36293995-0DBF9FB8-A4AC-43A7-80E3-7BF131A21A94Q36316871-A8FAFBF7-3443-4F3B-91E3-B616A51CA1DC
P2860
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Tumor regression and growth ra ...... cator of therapeutic efficacy.
@ast
Tumor regression and growth ra ...... cator of therapeutic efficacy.
@en
Tumor regression and growth ra ...... cator of therapeutic efficacy.
@nl
type
label
Tumor regression and growth ra ...... cator of therapeutic efficacy.
@ast
Tumor regression and growth ra ...... cator of therapeutic efficacy.
@en
Tumor regression and growth ra ...... cator of therapeutic efficacy.
@nl
prefLabel
Tumor regression and growth ra ...... cator of therapeutic efficacy.
@ast
Tumor regression and growth ra ...... cator of therapeutic efficacy.
@en
Tumor regression and growth ra ...... cator of therapeutic efficacy.
@nl
P2093
P1476
Tumor regression and growth ra ...... icator of therapeutic efficacy
@en
P2093
Doug Price
James L Gulley
Jeff Schlom
Phil M Arlen
Ravi A Madan
Susan E Bates
Wilfred D Stein
William D Figg
William Dahut
P304
P356
10.1158/1078-0432.CCR-10-1762
P407
P577
2010-11-24T00:00:00Z